Sanofi-Aventis (France) Gets Non-Approvable Letter From US FDA For Dronedarone
PARIS, Aug 31 (Reuters) - Sanofi-Aventis (SASY.PA: Quote, Profile, Research) said on Thursday that U.S health authorities had rejected its application for dronedarone, a heart arrythmia treatment branded as Multaq.